Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1981 2
1982 2
1983 2
1984 6
1985 7
1986 4
1987 7
1988 9
1989 5
1990 7
1991 8
1992 4
1993 10
1994 5
1995 2
1996 7
1997 4
1998 5
1999 3
2000 3
2001 3
2002 3
2003 1
2004 2
2005 4
2006 2
2007 1
2008 3
2009 1
2010 3
2011 1
2012 6
2013 6
2014 11
2015 12
2016 11
2017 19
2018 6
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

190 results
Results by year
Filters applied: . Clear all
Page 1
Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
Keating GM. Drugs 2015 - Review. PMID 25559422
This article reviews the clinical efficacy and tolerability of droxidopa in symptomatic neurogenic orthostatic hypotension, as well as summarizing its pharmacological properties. ...More data are needed to confirm the longer-term efficacy of droxidopa. Droxidopa was generally well tolerated, although patients should be monitored for supine hypertension....
This article reviews the clinical efficacy and tolerability of droxidopa in symptomatic neurogenic orthostatic hypotension, as well a …
Orthostatic hypotension for the cardiologist
Mar PL and Raj SR. Curr Opin Cardiol 2018 - Review. PMID 28984649 Free PMC article.
Finally, the United States Food and Drug Administration (FDA) recently approved droxidopa, a synthetic oral norepinephrine prodrug, in 2014 for the treatment of neurogenic orthostatic hypotension (nOH), and it represents a well tolerated, effective, and easy to use intervention for nOH. ...
Finally, the United States Food and Drug Administration (FDA) recently approved droxidopa, a synthetic oral norepinephrine prodrug, i …
Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment
Ricci F, et al. J Am Coll Cardiol 2015 - Review. PMID 26271068 Free article.
In this review, we outline the etiology and prevalence of OH in the general population, summarize its relationship with morbidity and mortality, propose a diagnostic and therapeutic algorithm, and delineate current challenges and future perspectives....
In this review, we outline the etiology and prevalence of OH in the general population, summarize its relationship with morbidity and mortal …
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
Chen JJ, et al. Ann Pharmacother 2018. PMID 29972032
Comparative analysis revealed a significant credible difference between droxidopa and midodrine. The RR for supine hypertension was significantly greater for midodrine, but not droxidopa, when compared with placebo (droxidopa RR = 1.4 [95% CrI = 0.7-2.7] and midodrine RR = 5.1 [95% CrI = 1.6-24]). ...However, midodrine, but not droxidopa, significantly increases risk of supine hypertension....
Comparative analysis revealed a significant credible difference between droxidopa and midodrine. The RR for supine hypertension was s …
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I, et al. BMC Neurol 2017 - Clinical Trial. PMID 28494751 Free PMC article.
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepinephrine), but its efficacy was numerically greater in non-DDCI users. Droxidopa was well-tolerated. Rates of most adverse events were similar between groups. Supine hypertension rates were low, but slightly higher in patients receiving droxidopa (≤7.9% vs ≤4.6% for placebo); patients with severe hypertension at screening were excluded from these studies. ...
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepi
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Palma JA, et al. Neurology 2018 - Clinical Trial. PMID 30232253 Free PMC article.
CONCLUSIONS: In patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa treatment. This finding should help identify patients with nOH most likely to respond to standard doses of droxidopa. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower supine plasma NE levels accurately identify patients with nOH more likely to have a greater pressor effect from droxidopa....
CONCLUSIONS: In patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa tr …
The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S, et al. Liver Int 2015. PMID 24517276
BACKGROUND & AIMS: Droxidopa improves hemodynamic and renal alterations of cirrhotic rats without changing portal pressure. We aimed to evaluate the effects of a combined treatment with droxidopa and non-selective beta-blockers or statins in order to decrease portal pressure, while maintaining droxidopa beneficial effects. ...Atorvastatin + droxidopa combination also failed to reduce PP, but maintained the beneficial increase in MAP and superior mesenteric artery resistance (SMAR) and decrease in blood flow (SMABF) caused by droxidopa. ...
BACKGROUND & AIMS: Droxidopa improves hemodynamic and renal alterations of cirrhotic rats without changing portal pressure. We ai …
190 results
Jump to page
Feedback